Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 7:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 96 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Total Survival Clear all
Completed Phase 2 Interventional Results available

Red Blood Cell (RBC) Survival Following Transfusion in Infants

NCT00731588
View directory record Official record
Conditions
Neonatal Anemia
Interventions
Transfused Biotin RBCs - Adults Phase I, Transfused Biotin RBCs - Infants Phase II, Transfused Biotin RBCs - Infants Phase III
Biological
Lead sponsor
John A Widness
Other
Eligibility
1 Hour to 6 Months
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
2
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Sep 7, 2026, 7:13 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Stability of Revision Total Hip Arthroplasty Implants Using Radiostereometric Analysis

NCT01668160
View directory record Official record
Conditions
Osteoarthritis of Hip, Failure of Primary THA
Interventions
Bead placement during revision hip replacement surgery
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2013 · Synced Sep 7, 2026, 7:13 AM EDT
Not yet recruiting Not applicable Interventional

Medically Tailored Meals to Reduce Ultra-processed Food Intake in Colorectal Cancer Survivors

NCT07701707
View directory record Official record
Conditions
Colorectal Cancer (Diagnosis)
Interventions
MTM: Medically tailored meals, MTM plus Fresh Produce, Control group
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 7, 2026, 7:13 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer

NCT02999854
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Interventions
ATIR101, Cyclophosphamide, T-cell depleted HSCT from a related, haploidentical donor, T-cell replete HSCT from a related, haploidentical donor
Biological · Drug · Procedure
Lead sponsor
Kiadis Pharma
Industry
Eligibility
18 Years to 70 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
12
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Sep 7, 2026, 7:13 AM EDT
Not listed Not applicable Interventional

Long-Term Multi-center Evaluation of E-Poly and Regenerex

NCT00545285
View directory record Official record
Conditions
Osteoarthritis of Hip, Traumatic Arthritis of Hip
Interventions
Total Hip Arthroplasty
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 75 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Sep 7, 2026, 7:13 AM EDT
Completed Phase 2 Interventional

Survival TRaining for ENhancing Total Health (STRENGTH)

NCT00068458
View directory record Official record
Conditions
Breast Cancer, Depression, Weight Changes
Interventions
Calcium-Rich Diet, Arm 2: Exercise + Calcium-Rich Diet, Exercise + Fruit & Vegetable, Low Fat + Calcium Diet
Dietary Supplement · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
4
States / cities
Durham, North Carolina • Goldsboro, North Carolina • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Sep 7, 2026, 7:13 AM EDT
Completed Early Phase 1 Interventional

Study of the Effect of GM-CSF on Macrophages in Ependymoma

NCT04408092
View directory record Official record
Conditions
Ependymoma, Recurrent Childhood, Ependymoma
Interventions
Granulocyte Macrophage Colony Stimulation Factor
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Months to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
2
States / cities
Denver, Colorado • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Sep 7, 2026, 7:13 AM EDT
Recruiting Phase 2 Interventional

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

NCT03509961
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
NGS-MRD, Myeloablative allogeneic HCT with a non-TBI conditioning regimen
Diagnostic Test · Drug
Lead sponsor
Pediatric Transplantation & Cellular Therapy Consortium
Other
Eligibility
1 Year to 25 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 7, 2026, 7:13 AM EDT
Completed Phase 2 Interventional Results available

Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation

NCT00248040
View directory record Official record
Conditions
Ischemia-Reperfusion Injury, Kidney Diseases
Interventions
Reparixin continuous infusion, reparixin intermittent infusion, placebo infusion
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Minneapolis, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Sep 7, 2026, 7:13 AM EDT
Withdrawn Not applicable Interventional

EDITS Pilot Study for Gynecologic Cancer Survivors

NCT05466916
View directory record Official record
Conditions
Gynecologic Cancer
Interventions
Exercise and diet education and instruction
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Sep 7, 2026, 7:13 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

NCT02205762
View directory record Official record
Conditions
Langerhans Cell Histiocytosis
Interventions
Prednisone, Vinblastine, mercaptopurine, INDOMETHACIN, Methotrexate, Cytosine Arabinoside, 2-chlorodeoxyadenosine, hematopoietic stem cell transplantation (RIC-HSCT), Intravenous immunoglobulin
Drug · Procedure · Biological
Lead sponsor
North American Consortium for Histiocytosis
Other
Eligibility
Up to 18 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 7, 2026, 7:13 AM EDT
Active, not recruiting Phase 2 Interventional

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

NCT04743661
View directory record Official record
Conditions
Recurrent Medulloblastoma, Recurrent Ependymoma
Interventions
Irinotecan, Temozolomide, Bevacizumab, Omburtamab I-131, Liothyronine, SSKI, Dexamethasone, Antipyretic, Antihistamine, anti-emetics
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 21 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Los Angeles, California • New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 7, 2026, 7:13 AM EDT
Completed Phase 2 Interventional Results available

Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma

NCT00878254
View directory record Official record
Conditions
Mantle-Cell Lymphoma
Interventions
G-CSF, Rituximab, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Ifosfamide, Leucovorin, Mesna, Methotrexate, Vincristine
Biological · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Sep 7, 2026, 7:13 AM EDT
Completed Phase 1Phase 2 Interventional

Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL

NCT00529360
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
Interventions
Clofarabine
Drug
Lead sponsor
New York Medical College
Other
Eligibility
Up to 30 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Vallhala, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Sep 7, 2026, 7:13 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Maxx Orthopedics' PCK Revision TKA Study of Component Survivorship

NCT03312088
View directory record Official record
Conditions
Aseptic Loosening, Infection, Bone Loss, MCL - Medial Collateral Ligament Rupture of the Knee, Periprosthetic Fractures
Interventions
Freedom Knee PCK Components
Device
Lead sponsor
Maxx Orthopedics Inc
Industry
Eligibility
40 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bradenton, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Sep 7, 2026, 7:13 AM EDT
Not listed Not applicable Interventional

Long-Term Multicenter Evaluation of the E1® Tibial Bearing

NCT01374230
View directory record Official record
Conditions
Osteoarthritis of the Knee, Traumatic Arthritis of the Knee
Interventions
Total knee arthroplasty
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 75 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 29, 2018 · Synced Sep 7, 2026, 7:13 AM EDT
Not listed Not applicable Interventional

Medium Term Survivorship of Cementless THA Performed Using the Bone Preservation Tri-Lock Femoral Stem

NCT01566916
View directory record Official record
Conditions
Total Hip Arthroplasty
Interventions
Total Hip Arthroplasty
Procedure
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Egg Harbor, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Sep 7, 2026, 7:13 AM EDT
Not listed Not applicable Interventional

Evaluation of the Wear of Vitamin E Treated Polyethylene Components in Primary THA Using RSA

NCT00551967
View directory record Official record
Conditions
Osteoarthritis of Hip, Traumatic Arthritis of Hip
Interventions
Hip replacement
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Sep 7, 2026, 7:13 AM EDT
Recruiting Not applicable Interventional

Promoting Resilience in Women With Breast Cancer (PRISM -MBC)

NCT06855654
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer
Interventions
Promoting Resilience in Women with Breast Cancer (PRISM)
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Birmingham, Alabama • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 7, 2026, 7:13 AM EDT
Completed Phase 2 Interventional Results available

Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer

NCT00022698
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Capecitabine, Irinotecan
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
17
States / cities
Birmingham, Alabama • Loma Linda, California • Norwich, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Sep 7, 2026, 7:13 AM EDT
Not listed Phase 1Phase 2 Interventional

Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors

NCT00679536
View directory record Official record
Conditions
Leukemia
Interventions
Busulfan, Fludarabine, Thymoglobulin, Total Body Irradiation
Drug · Radiation
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Up to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Sep 7, 2026, 7:13 AM EDT
Completed No phase listed Observational

Post-Approval Study to Investigate the Long Term (8 Year) Survivorship of STAR Ankle Among Continued Access Study Patients

NCT01288586
View directory record Official record
Conditions
Primary Arthrosis
Interventions
Scandinavian Total Ankle Replacement System (STAR Ankle)
Device
Lead sponsor
Stryker Trauma and Extremities
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
5
States / cities
Oakland, California • Temple Terrace, Florida • Boise, Idaho + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Sep 7, 2026, 7:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Don't Throw Your Heart Away: Layperson Study 1

NCT04133831
View directory record Official record
Conditions
Cardiac Transplant Disorder
Interventions
Total Survival, Stratified Transplant Survival
Other
Lead sponsor
Carnegie Mellon University
Other
Eligibility
18 Years and older
Enrollment
1,019 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 7, 2026, 7:13 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor

NCT03707262
View directory record Official record
Conditions
Renal Transplant Rejection, Tolerance, Kidney Transplant
Interventions
Donor CD34+ and CD3+ cells
Biological
Lead sponsor
Jeffrey Veale, MD
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 7, 2026, 7:13 AM EDT